Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
22 studies found for:    Schilder's Disease
Show Display Options
Rank Status Study
1 Recruiting Alpers Huttenlocher Natural History Study
Condition: Alpers Huttenlocher Syndrome
Intervention:
2 Unknown  Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone
Conditions: Acute Disseminated Encephalomyelitis;   Devic's Syndrome;   Marburg's Variant of Multiple Sclerosis;   Balo's Concentric Sclerosis;   Acute Transverse Myelitis
Intervention: Procedure: Plasma exchange
3 Recruiting Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Malignant Ovarian Endometrioid Tumor;   Malignant Ovarian Serous Tumor;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Topotecan Hydrochloride;   Drug: Acetylcysteine
4 Completed
Has Results
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Dasatinib;   Other: Laboratory Biomarker Analysis
5 Completed
Has Results
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Intervention: Drug: irofulven
6 Completed Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
7 Completed Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Conditions: Cervical Squamous Cell Carcinoma;   Recurrent Cervical Cancer
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
8 Completed
Has Results
Effectiveness of Sulfamethoxazole-trimethoprim in the Treatment of Chronic Otitis Media
Condition: Chronic Otitis Media
Interventions: Drug: Sulfamethoxazole-trimethoprim;   Drug: Placebo
9 Terminated A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Neoplasms
Intervention: Drug: Volociximab
10 Completed Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: filgrastim;   Biological: recombinant human stem cell factor;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: etoposide;   Drug: melphalan;   Drug: mitoxantrone hydrochloride;   Drug: paclitaxel;   Procedure: peripheral blood stem cell transplantation
11 Recruiting Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Endometrial Undifferentiated Carcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Tumor;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Tumor;   Ovarian Transitional Cell Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
12 Unknown  Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Elesclomol Sodium;   Drug: Paclitaxel
13 Recruiting Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Conditions: Micropapillary Serous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Tamoxifen Citrate;   Drug: Topotecan Hydrochloride;   Drug: Trametinib
14 Terminated Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Primary Peritoneal Carcinoma;   Stage III Ovarian Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Paclitaxel;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Topotecan Hydrochloride
15 Completed Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: isotretinoin
16 Completed Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Intervention: Drug: gefitinib
17 Completed AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Intervention: Drug: motesanib diphosphate
18 Completed Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Biological: filgrastim;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: paclitaxel;   Drug: topotecan hydrochloride;   Procedure: peripheral blood stem cell transplantation
19 Terminated Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Condition: Cervical Cancer
Intervention: Drug: gemcitabine hydrochloride
20 Recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Conditions: Advanced Malignant Neoplasm;   Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Plasma Cell Myeloma;   Refractory Malignant Neoplasm;   Refractory Plasma Cell Myeloma
Interventions: Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Trk Inhibitor LOXO-101;   Drug: Vismodegib;   Drug: WEE1 Inhibitor AZD1775

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.